Next Article in Journal
Influence of ShuJinHuoXue Tablets on Ischemia Reperfusion Injury of Animals’ Skeletal Muscle
Previous Article in Journal
Antimycobacterial Activity of Constituents from Foeniculum vulgare Var. Dulce Grown in Mexico
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 17
Issue 7
10.3390/molecules17078483
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis, Tautomeric Structure and Antimicrobial Activity of 3-Arylhydrazono-4-phenyl-[1,2,4]-triazepino[2,3-a]quinazoline-2,7(1H)-diones

by
Thoraya Abdel Reheem Farghaly
1,
Mastoura Mohamed Edrees
2,† and
Mosselhi Abdelnabi Mosselhi
1,3,*
1
Department of Chemistry, Faculty of Science, University of Cairo, Giza 12311, Egypt
2
Department of Organic Chemistry, National Organization for Drug Control and Research (NODCAR), Giza 12311, Egypt
3
Department of Chemistry, Faculty of Science, Taif University, Taif-888, Saudi Arabia
*
Author to whom correspondence should be addressed.
†
Present address: Department of Chemistry, Faculty of Science, King Khalid University, P.O. Box 9004, ABHA-61413, Saudi Arabia.
Molecules 2012, 17(7), 8483-8493; https://doi.org/10.3390/molecules17078483
Submission received: 24 May 2012 / Revised: 25 June 2012 / Accepted: 3 July 2012 / Published: 13 July 2012
(This article belongs to the Section Organic Chemistry)
Browse Figures
Versions Notes

Abstract

:
A simple strategy for the synthesis of the hitherto unreported 3-arylazo-4-phenyl- [1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-diones is described. Spectral data indicated that the studied compounds exist predominantly in the hydrazone tautomeric form. The antimicrobial activity of the newly synthesized compounds was also evaluated. The results indicated that some of these compounds have moderate activity towards bacteria.

Graphical Abstract

1. Introduction

4(3H)-Quinazolinone has to be the most used heterocycle in medicinal chemistry [1,2,3] and it is considered as a key building block for natural alkaloids [4]. A wide spectrum of biological effects is reported for compounds containing the quinazoline ring system. For example, many quinazoline derivatives show antifungal [5], antitoxoplasmosis [6], anti-HIV-I agent [7], antitumour [8,9,10], anti-allergic and antihypertensive properties [11]. They also have been used to prevent ocular inflammatory reactions [12]. 2-Thioxo-4(1H)-quinazolinones are important derivative of quinazolinones found to possess a variety of bioactivities and are good precursors for the synthesis of fused quinazolines [13,14,15]. 2,3-Diaminoquinazolinone is reported to be the key for synthesis of derivatives of thiazolo[4,3-b]benzothiazole, thiazolo[3',4':2,3], [1,2,4]-triazolo[5,1-b]-, {triazino[3,2-b]- and triazepino[3,2-b]}-quinazolines [16]. 2-Thioxo-1H-4-quinazolinones are also versatile intermediates for fused heterocyclo quinazolinones like 2-phenyl-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one, 3-(4-bromophenyl)-2H,6H-[1,3,4]thiadiazino-[2,3-b]quinazolin-6-one, 4-amino-2-phenyl-3a,4-dihydro-2H-thiazolo[3,2a]quinazoline -1,5-dione and 2-phenyl-[1,3,4]thiadiazino[2,3-b]quinazoline-3,6(2H,4H)-dione [17].
It has been reported recently that the azo-hydrazone tautomerism of diazonium coupling products of acyclic and heterocyclic active methylene compounds in both ground and excited states is useful in the field of material sciences [18,19,20,21,22,23,24].
Due to the forgoing importance of quinazoline derivatives and as a part of our program of studies on the chemistry of bioactive molecules and azo-hydrazone tautomerism [18,19,20,21,22,23,24], it was thought interesting to study the synthesis of 4-phenyl-1,3-dihydro[1,2,4]triazepino[2,3-a]quinozalin-2,7-dione (4) (Scheme 1) and its reaction with diazonium salts 5 in an attempt to synthesize the respective title compounds, 3-arylhydrazino-4-phenyl-[1,2,4]triazepino[2,3-a]quinazolin-2,7(1H)-diones, 6 (Scheme 2) and to study their tautomeric structures. This is because such products can have one or more of the four tautomeric structures A–D shown in Figure 1. In addition, the products 6 obtained were tested for their biological activity which is also reported.
Molecules 17 08483 g002 550
Scheme 1. Synthesis of 4-phenyl-1,3-dihydro[1,2,4]triazepino[2,3-a]quinozalin-2,7-dione (4).
Scheme 1. Synthesis of 4-phenyl-1,3-dihydro[1,2,4]triazepino[2,3-a]quinozalin-2,7-dione (4).
Molecules 17 08483 g002
Molecules 17 08483 g003 550
Scheme 2. Synthesis of 3-arylhydrazino-4-phenyl-[1,2,4]triazepino[2,3-a]quinazolin-2,7(1H)-dione (6a–j).
Scheme 2. Synthesis of 3-arylhydrazino-4-phenyl-[1,2,4]triazepino[2,3-a]quinazolin-2,7(1H)-dione (6a–j).
Molecules 17 08483 g003
Molecules 17 08483 g001 550
Figure 1. Four tautomeric structures A–D of 4.
Figure 1. Four tautomeric structures A–D of 4.
Molecules 17 08483 g001

2. Results and Discussion

The starting 4-phenyl-1,3-dihydro-[1,2,4]triazepino[2,3-a]quinazoline-2,7-dione 4 was prepared by condensation of 2,3-diamino-quinazolin-4-one 1 [25] with ethyl benzoylacetate 2 in acetic acid under reflux. The structure of 4 was indicated by its elemental and spectral (IR, 1H-NMR and MS) analyses (see the experimental section). As shown in Scheme 1, the reaction of 1 with 2 could in principle yield 4 and/or its isomer, namely, 2-phenyl-3,5-dihydro[1,2,4] triazepino[2,3-a]quinazoline-4,7-dione (3), but the latter isomeric structure was discarded. because condensation reactions of ethyl benzoylacetate with C,N-1,2-diaminoheterocycles thus far studied were reported to be regioselective and lead to products that result from nucleophilic attack of the N-NH2 and the C-NH2 groups at the keto and ester carbonyl groups of the β-keto ester, respectively to give the corresponding fused 4-oxo-1,2,4-triazepine derivatives [26,27,28]. This regioselectivity was substantiated by X-ray crystallographic analysis in some cases [28] and by spectral data [26,27,28].
The structure 4 can exist in one of the possible tautomeric forms 4A–D as shown in Figure 1. The isomeric form 4A is the predominant one based on the spectral data (MS, 1H-NMR and IR). For example, the 1H-NMR spectrum revealed three characteristic signals near δ 4.52, 7.38–8.22 and 13.15 which are assignable to CH2, C6H5 and the ring NH protons, respectively. Also, the mass spectrum of compound 4 showed the molecular ion peak at m/z 304, which is consistent with its structural formula.
Reaction of 4 with diazotized anilines in basic medium afforded the respective arylazo derivatives 6 (Scheme 2). The mass spectra of the latter products revealed the molecular ion peaks at the expected m/z values and their elemental analyses data were consistent with their assigned structures. The infrared spectral data of compounds 6 (see Experimental) seem to be consistent more with the hydrazone tautomeric form 6A rather than the other tautomeric forms 6B–E (Scheme 2). For example, all compounds exhibit two carbonyl bands in the regions 1715–1681 and 1698–1643 cm−1 corresponding to the stretching vibrations of the pyrimidinone and the 1,2,4-triazepinone carbonyl groups, respectively. The observed wave number of the latter CO stretching band in compounds 6 seems to result from the possible strong hydrogen bond with the hydrazone NH and conjugation with the C=N double bond as required by the hydrazone form 6A (Scheme 2) [29].
To elucidate the actual tautomeric form of the studied compounds 6, we investigated their electronic absorption spectra. The data are summarized in Table 1. As shown, each of compounds 6 in dioxane exhibits three characteristic absorption bands in the regions 385–346, 328–248 and 257–231 nm. Such an absorption pattern is similar to that of typical hydrazone chromophore [23,24]. Furthermore, the spectrum of 6d, taken as a typical example of the series studied was recorded in variety solvents with different polarities. The spectra obtained showed little, if any, shift (Table 1).
The small shifts in λmax of 6d in different solvents are due to solute-solvent interaction. In agreement with this conclusion, is the observation that the spectra of arylhydrazones derived from the reaction of quinones with N-alkyl-N-phenylhydrazine, unlike those of o- and p-hydroxyazo compounds, are largely independent of the solvent polarity [30]. This finding, while it excludes the azo tautomeric forms 6B, 6D and 6E, indicates that each of compounds 6 exist in one tautomeric form, namely 6A(Scheme 2).
Table
Table 1. UV Spectra of 3-arylhydrazono-4-phenyl-1H-[1,2,4]triazepino[2,3-a]quinazolin-2,7-diones 6a–j in dioxane.
Table 1. UV Spectra of 3-arylhydrazono-4-phenyl-1H-[1,2,4]triazepino[2,3-a]quinazolin-2,7-diones 6a–j in dioxane.
Compd. No.λmax (log ε)
6a385 (3.72), 321 (4.22), 257 (4.63)
6b381 (4.52), 260 (4.57), 231 (4.78)
6c375 (4.02), 282 (4.82), 247 (4.81)
6d a)370 (4.45), 248 (4.63)
6e372 (4.25), 286 (4.26), 231 (4.55)
6f372 (4.10), 328 (4.39), 233 (5.13)
6g346 (3.62), 267 (4.78), 232 (5.01)
6h383 (4.62), 260 (4.54), 234 (4.80)
6i372 (3.94), 260 (3.68), 235 (4.01)
6j381 (4.52), 260 (4.57), 231 (4.78)
a) Solvent λmax (logε): acetic acid 370 (4.36), 248 (4.00); acetonitrile 370 (3.80), 246 (4.11); DMF 367 (4.01), 247 (4.14); ethanol 371 (3.60), 249 (3.70).

2.1. Anti-Microbial Activity

In vitro anti-microbial screening of compounds 4 and 6a–j prepared in this study was carried out using two bacteria species, including a Gram negative bacterium, Escherichia coli (RCMB 000103) (EC) and a Gram positive bacterium, Staphylococcus aureus (RCMB 000106) (SA) and twofungal strains, namely Aspergillus fumigatus (RCMB 002003) (AF) and Candida albicans (RCMB 005002) (CA) using the agar diffusion well method (see Experimental). The microorganisms were tested against the activity of solutions of concentrations of 1.0 mg/mL of each compound in dimethylsulfoxide (DMSO) and using an inhibition zone diameter in cm (IZD) as criterion for the antimicrobial activity. The fungicide amphotericin B and the bactericide tetracycline were used as references to evaluate the potency of the tested compounds under the same conditions. The results, depicted in Table 2, showed that compounds 6a, e, h–j displayed moderate activities against E. coli and S. aureus, while, none of the tested compounds have any activity against A. fumigatus and C. albicans. These biological activities of compounds 6a–j are far less than the studied reference drugs (tetracycline and amphotericin B).
Table
Table 2. Antimicrobial Activity of the newly synthesized compounds.
Table 2. Antimicrobial Activity of the newly synthesized compounds.
Microorganism/IZD (mm/mg sample) *
Cpd. no.EC(G−)SA (G+)AFCA
Control (DMSO)0.00.00.00.0
4009000.0
6a12110.00.0
6b00000.00.0
6c00000000
6d00000000
6e13120000
6f00000000
6g9000000
6h11120000
6i11110000
6j12120000
Te **3129----
Am **----1720
* IZD, inhibition zone diameter, ** Te = Tetracycline used as standard antibacterial agent and** Am = Amphotericin B used as standard antifungal agent.

3. Experimental Section

3.1. General

Melting points were determined on a Gallenkamp apparatus and are uncorrected. IR spectra were recorded in potassium bromide pellets using Perkin Elmer FTIR 1650 and Pye-Unicam SP300 infrared spectrophotometers. 1H-NMR and 13C-NMR spectra were recorded in deuterated dimethyl sulfoxide (DMSO-d6) using a Varian Gemini 300 NMR spectrometer. Mass spectra were recorded on a GCMS-QP 1000 EX Shimadzu and GCMS 5988-A HP spectrometers. Electronic absorption spectra were recorded on Perkin-Elmer Lambada 40 spectrophotometer. Elemental analyses were carried out at the Microanalytical Laboratory of Cairo University, Giza, Egypt. 2,3-Diamino-quinazoline-4-one 1 was prepared as previously described [25].
4-Phenyl-1,3-dihydro-[1,2,4]triazepino[2,3-a]quinazoline-2,7-dione (4). A mixture of 2,3-diamino-quinazolin-4-one (1, 1.76 g, 10 mmol) and ethyl benzoylacetate (2, 2.4 g, 3 mL, 20 mmol) in acetic acid (20 mL) was refluxed for 30 h and cooled. The solid that precipitated was collected and crystallized from ethanol to give compound 4 as yellow crystalline solid, yield (40%). mp. 282–284 °C. 1H-NMR (DMSO-d6) δ 4.56 (s, 2H, CH2), 7.35–8.22 (m, 9H, ArH), 13.15 (s, 1H, NH). MS m/z (%) 305 (M+ + 1, 1), 304 (M+, 10), 176 (13), 157 (18), 144 (32), 104 (46), 77 (77), 76 (100). Anal. Calcd for C17H12N4O2 (304.30): C, 67.10; H, 3.97; N, 18.41; Found: C, 67.24; H, 3.86; N, 18.25%.

3.2. General Procedure for Synthesis of 3-Arylhydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-diones (6a–j).

To a stirred solution of compound 4 (1.52 g, 5 mmol) in ethanol (40 mL) was added sodium hydroxide (0.2 g, 5 mmol) and the mixture was cooled in an ice bath at 0–5 °C. To the resulting solution, while being stirred, was added dropwise over a period of 20 min, a solution of the appropriate arenediazonium chloride, prepared as usual by diazotizing the respective aniline (5 mmol) in hydrochloric acid (6 M, 3 mL) with sodium nitrite (1 M, 5 mL). The whole mixture was then left in a refrigerator overnight. The precipitated solid was collected, washed with water and finally crystallized from ethanol to give the respective hydrazones 6a–j.
3-(4-Methoxyphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6a). This compound was obtained as red solid, (68%). mp. 246–248 °C. 1H-NMR (DMSO-d6) δ 3.82 (s, 3H, OCH3), 6.92 (d, J = 9 Hz, 2H, ArH), 7.07–7.910 (m, 9H, ArH), 7.92 (d, J = 9 Hz, 2H, ArH), 12.20 (s, 1H, NH), 13.44 (s, 1H, NH); IR (KBr) νmax 3400, 3147 (2NH), 1705, 1681 (2CO) cm−1. MS m/z (%) 439 (M+ + 1, 2), 438 (M+, 7), 122 (14), 105 (100), 77 (41). Anal. Calcd for C24H18N6O3 (438.44): C, 65.75; H, 4.14; N, 19.17; Found: C, 65.64; H, 4.10; N, 19.09%.
3-(4-Methylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6b). This compound was obtained as brown solid, (69%). mp. 232–236 °C. 1H NMR (DMSO-d6) δ 2.45 (s, 3H, CH3), 7.05 (d, J = 8 Hz, 2H, ArH), 7.14–7.94 (m, 9H, ArH), 8.26 (d, J = 8 Hz, 2H, ArH), 12.07 (s, 1H, NH), 13.84 (s, 1H, NH); 13C NMR(DMSO-d6) δ 20.30, 113.39, 114.36, 115.87, 116.63, 121.40, 122.73, 125.15, 126.52, 127.28, 127.99, 128.93, 129.91, 131.48, 132.09, 138.53, 140.31, 159.41, 163.77, 164.25. IR (KBr) νmax 3471, 3406 (2NH), 1697, 1651 (2CO) cm−1. MS m/z (%) 422 (M+, 31), 317 (5 ), 211 (7), 105 (100), 90 (18), 77 (44). Anal. Calcd for C24H18N6O2 (422.44): C, 68.24; H, 4.29; N, 19.89; Found: C, 68.17; H, 4.31; N, 19.74%.
3-(3-Methylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6c). This compound was obtained as yellow solid, (59%). mp. 200–204 °C. 1H-NMR (DMSO-d6) δ 2.24 (s, 3H, CH3), 6.84–8.30 (m, 13H, ArH), 11.90 (s, 1H, NH), 13.33 (s, 1H, NH); IR (KBr) νmax 3433, 3100 (2NH), 1712, 1685 (2CO) cm−1. MS m/z (%) 422 (M+, 10), 211 (11), 130 (10), 105 (100), 90 (12), 77 (55). Anal. Calcd for C24H18N6O2 (422.44): C, 68.24; H, 4.29; N, 19.89; Found: C, 68.10; H, 4.21; N, 19.68%.
3-Phenylazohydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6d). This compound was obtained as yellow solid, (82%). mp. 244–246 °C. 1H NMR (DMSO-d6) δ 7.03–8.30 (m, 14 H, ArH), 11.90 (s, 1H, NH), 13.50 (s, 1H, NH); 13C NMR (DMSO-d6) δ 112.31, 115.23, 117.11, 120.95, 123.06, 124.19, 125.06, 126.34, 128.34, 129.07, 131.11, 132.26, 136.44, 138.60, 141.36, 156.20, 159.92, 161.23, 162.15. IR (KBr) νmax 3471, 3178 (2NH), 1700, 1654 (2CO) cm−1. MS m/z (%) 408 (M+, 64), 407 (71), 144 (25), 134 (15), 105 (84), 91 (100), 77 (76). Anal. Calcd for C23H16N6O2 (408.41): C, 67.64; H, 3.95; N, 20.58; Found: C, 67.50; H, 4.09; N, 20.38%.
3-(3-Chlorophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6e). This compound was obtained as yellow solid, (75%). mp. 180–182 °C. 1H-NMR (DMSO-d6) δ 7.34–8.19 (m, 13H, ArH), 11.32 (s, 1H, NH), 13.22 (s, 1H, NH); IR (KBr) νmax 3401, 3100 (2NH), 1689, 1654 (2CO) cm−1. MS m/z (%) 444 (M+ + 2, 1), 443 (M+ + 1, 4), 442 (M+, 3), 211 (15), 122 (16), 111 (6), 104 (100), 90 (10), 76 (50). Anal. Calcd for C23H15ClN6O2 (442.86): C, 62.38; H, 3.41; N, 18.98; Found: C, 62.29; H, 3.34; N, 18.79%.
3-(4-Chlorophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6f). This compound was obtained as yellow solid, (80%). mp. 240–242 °C. 1H-NMR (DMSO-d6) δ 7.12–7.95 (m, 9H, ArH), 8.05 (d, J = 8 Hz, 2H, ArH), 8.18 (d, J = 8 Hz, 2H, ArH), 11.82 (s, 1H, NH), 13.20 (s, 1H, NH); 13C NMR(DMSO-d6) δ 115.23, 117.17, 118.01, 122.84, 125.29, 126.20, 127.03, 128.42, 129.18, 129.56, 131.30, 132.16, 137.54, 138.19, 142.30, 154.36, 158.90, 162.21, 163.56. IR (KBr) νmax 3282, 3186, (2NH), 1681, 1647 (2CO) cm−1. MS m/z (%) 444 (M+ + 2, 2), 442 (M+, 5), 304 (83), 276 (33), 130 (11), 111 (2), 105 (100), 89 (14), 76 (87). Anal. Calcd for C23H15ClN6O2 (442.86): C, 62.38; H, 3.41; N, 18.98; Found: C, 62.19; H, 3.25; N, 18.88%.
3-(3-Nitrophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6g). This compound was obtained as yellowish brown solid, (64%). mp. 286–288 °C. 1H-NMR (DMSO-d6) δ 7.10–8.15 (m, 12H, ArH), 8.33 (s, 1H, ArH), 11.39 (s, 1H, NH), 13.61 (s, 1H, NH); IR (KBr) νmax 3440, 3224 (2NH), 1700, 1651 (2C=O) cm−1. MS m/z (%) 453 (M+, 15), 144 (12), 118 (15), 105 (100), 91 (23), 76 (54). Anal. Calcd for C23H15N7O4 (453.41): C, 60.93; H, 3.33; N, 21.62; Found: C, 60.85; H, 3.21; N, 21.49%.
3-(4-Nitrophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6h). This compound was obtained as dark red solid, (76%). mp. 268–270 °C. 1H-NMR (DMSO-d6) δ 7.13–7.30 and 7.44–8.01 (m, 9H, ArH), 7.33 (d, J = 8 Hz, 2H, ArH), 8.27 (d, J = 8 Hz, 2H, ArH), 11.54 (s, 1H, NH), 13.52 (s, 1H, NH); 13C NMR(DMSO-d6) δ 113.95, 120.77, 125.22, 127.30, 128.41, 128.89, 130.0, 132.29, 133.46, 134.71, 135.31, 136.61, 141.56, 143.02, 144.21, 148.78, 159.0, 162.26, 162.85. IR (KBr νmax 3440, 3379 (2NH), 1698, 1658 (2C=O) cm−1. MS m/z (%) 454 (M+ + 1, 2), 453 (M+, 25), 211 (13), 145 (9), 105 (100), 76 (52). Anal. Calcd for C23H15N7O4 (453.41): C, 60.93; H, 3.33; N, 21.62; Found: C, 60.79; H, 3.25; N, 21.71%.
3-(4-Acetylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6i). This compound was obtained as reddish brown solid, (71%). mp. 176–178 °C. 1H-NMR (DMSO-d6) δ 2.25 (s, 3H, COCH3), 7.08 (d, J = 8 Hz, 2H, ArH), 7.38–7.94 (m, 9H, ArH), 8.06 (d, J = 8 Hz, 2H, ArH), 11.96 (s, 1H, NH), 12.40 (s, 1H, NH); 13C-NMR (DMSO-d6) δ 55.29, 114.0, 114.60, 114.89, 115.32, 119.32, 125.05, 126.10, 127.91, 129.32, 129.83, 131.82, 132.11, 136.69, 138.66, 150.78, 155.05, 155.52, 156.81, 157.11, 190.26. IR (KBr) νmax 3429, 3356 (2NH), 1715, 1698, 1658 (3C=O) cm−1. MS m/z (%) 451 (M+ + 1, 1), 450 (M+, 5), 303 (21), 104 (100), 76 (41). Anal. Calcd for C25H18N6O3 (450.45): C, 66.66; H, 4.03; N, 18.66; Found: C, 66.48, H, 4.20, N, 18.50%.
3-(4-Ethoxycarbonylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6j). This compound was obtained as reddish brown solid, (75%). mp. 180–182 °C 1H-NMR (DMSO-d6) δ 1.30 (t, J = 7 Hz, 3H, CH3 ), 4.26 (q, J = 7 Hz, 2H, CH2), 7.23 (d, J = 8 Hz, 2H, ArH), 7.43–7.99 (m, 9H, ArH), 8.26 (d, J = 8 Hz, 2H, ArH), 11.10 (s, 1H, NH), 12.12 (s, 1H, NH); IR (KBr) νmax 3394, 3150 (2NH), 1725, 1681, 1643 (3C=O) cm−1. MS m/z (%) 481 (M+ + 1, 3), 480 (M+, 16), 479 (10), 105 (100), 104 (17), 77 (43). Anal. Calcd for C26H20N6O4 (480.47): C, 64.99; H, 4.20.; N, 17.49; Found: C, 64.84, H, 4.10, N, 17.35%.

3.2. Agar Diffusion Well Method to Determine the Antimicrobial Activity

The microorganism inoculums were uniformly spread using sterile cotton swab on a sterile Petri dish containing Malt extract agar (for fungi) and nutrient agar (for bacteria). Each sample (100 μL) was added to each well (6 mm diameter holes cut in the agar gel, 20 mm apart from one another). The systems were incubated for 24–48 h at 37 °C (for bacteria) and at 28 °C (for fungi). After incubation, microorganism growth was observed. Inhibition of the bacterial and fungal growth were measured in mm. Tests were performed in triplicate p [31].

4. Conclusions

In this report, a simple method for the synthesis of 3-arylhydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]-quinazoline-2,7(1H)-dione was accomplished by the coupling of 4-phenyl-1,3-dihydro[1,2,4]-triazepino[2,3-a]quinazolin-2,7-dione and the diazonium salt of aniline derivatives. The tautomeric structure of the products was investigated. Their spectral data indicate collectively that such compounds exist predominantly in the hydrazone tautomeric form 6A. In addition, the antimicrobial activity of some of the products showed moderate activities against E. coli and S. aureus although these activities are far less than those of the studied reference drugs (tetracycline and amphotericin B).

References

  1. Maillard-Boyer, M.; Castera-Ducros, C.; Verhaeghe, P.; Sifredi, F.; Rathelot, P.; Vanelle, P. Access to original vinylic chlorides in the quinazoline series via a monoelectronic transfer reaction approach. Molecules 2010, 15, 2719–2729. [Google Scholar]
  2. Laddha, S.S.; Bhatnagar, S.P. Novel fused quinazolinones: Further studies on the anticonvulsant activity of 1,2,9,11-tetrasubstituted-7H-thieno[2′,3′:4,5]pyrimido[6,1-b]-quinazolin-7-one and 1,3,10,12-tetrasubstituted-8H-pyrido[2′,3′:4,5]pyrimido[6,1-b]quinazolin-8-one. Future Med. Chem. 2010, 2, 565–573. [Google Scholar] [CrossRef]
  3. Rohini, R.; Shanker, K.; Reddy, M.P.; Ravinder, V. Synthesis and antimicrobial activities of a new class of 6-arylbenzimidazo[1,2-c]quinazolines. J. Braz. Chem. Soc. 2010, 21, 49–57. [Google Scholar] [CrossRef]
  4. Saeed, A.; Shaheen, U.; Bolte, M. Synthesis, characterization and crystal structure of some novel 1-aryl-2-thioxo-2,3-dihydro-1H-quinazolin-4-ones. J. Chin. Chem. Soc. 2010, 57, 82–88. [Google Scholar]
  5. Shakhadoyatov, K.M.; Yangibaev, S.; Yun, L.M.; Kadyrov, C.S. Synthesis and alkylation of 2-mercapto-4-quinazolone and the fungicidal activities of the compounds obtained. Chem. Nat. Comp. 1982, 18, 106–109. [Google Scholar]
  6. El-Tombary, A.A.; Ismail, K.A.; Aboulwafa, O.M.; Omar, A.M.; El-Azzouni, M.Z.; El-Mansoury, S.T. Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect. Il Farmaco 1999, 54, 486–488. [Google Scholar]
  7. Gürsoy, A.; Karali, N. Synthesis and primary cytotoxicity evaluation of 3-[[(3-phenyl-4(3H)-quinazolinone-2-yl)mercaptoacetyl]hydrazono]-1H-2-indolinones. Eur. J. Med. Chem. 2003, 38, 633–643. [Google Scholar]
  8. Hamel, E.; Lin, C.M.; Plowman, J.; Wang, H.K.; Lee, K.H.; Paull, K.D. Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives: Interactions with tubulin. Biochem. Pharmacol. 1996, 51, 53–59. [Google Scholar]
  9. Xia, Y.; Yang, Z.Y.; Hour, M.-J.; Kuo, S.C.; Xia, P.; Bastow, K.F.; Nakanishi, Y.; Nampoothiri, P.; Hackl, T.; Hamel, E.; Lee, K. H. Antitumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett. 2001, 11, 1193–1196. [Google Scholar] [CrossRef]
  10. Peet, N.P.; Baugh, L.E.; Sundler, S.; Lewis, J.E.; Matthews, E.H.; Olberding, E.L.; Shah, D.N. 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): A new antiallergic agent. J. Med. Chem. 1986, 29, 2403–2409. [Google Scholar]
  11. Cross, P.E.; Dickison, R.P.; Parry, M.J.; Randall, M.J. Selective thromboxane synthetase inhibitors. 1. 1-[(aryloxy)alkyl]-1H-imidazoles. J. Med. Chem. 1985, 28, 1427–1432. [Google Scholar]
  12. Hankovszky, H.O.; Hideg, K.; Bódi, I.; Frank, L. New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethyl-pyrrolidine-3-carboxamides. J. Med. Chem. 1986, 29, 1138–1152. [Google Scholar] [CrossRef]
  13. Van Dyck, C.H.; Tan, P.-Z.; Baldwin, R.M.; Amici, L.A.; Garg, P.K.; Ng, C.K.; Soufer, R.; Charney, D.S.; Innis, R.B. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. J. Nucl. Med. 2000, 41, 234–241. [Google Scholar]
  14. Du, X.; Jiang, Y.; Qian, W.; Lu, X.; Walsh, J.P. Fatty acids inhibit growth-factor-induced diacylglycerol kinase alpha activation in vascular smooth-muscle cells. Biochem. J. 2001, 1, 275–282. [Google Scholar]
  15. Santagati, A.; Modica, M.; Monsu Scolaro, L.; Santagati, M. New synthetic approaches to fused heterocyclo-quinazolines. J. Chem. Res. (s) 1999, 86–87. [Google Scholar]
  16. Barghash, A.E.M.; El-Kerdawy, M.M.; Shehata, I.A.; Abdel-Aziz, N.I. Synthesis and antiviral testing of certain derivatives of thiazolo[4,3-b]benzothiazoles, thiazolo[3′,4′:2,3][1,2,4]-triazolo[5,1-b]-, {triazino [3,2-b]- and triazepino[3,2-b]}-quinazolines. Alex. J. Pharm. Sci. 2004, 18, 109–113. [Google Scholar]
  17. Tiwari, V.K.; Kale, R.R.; Mishra, B.B.; Singh, A. A facile one-pot MW approach for N3-(heteroaryl-2’-yl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one. ARKIVOC 2008, 14, 27–36. [Google Scholar]
  18. Mosselhi, M.A.; Pfleiderer, W. Syntheses, properties, and reactions of 8-aminoxanthines, purines. Part XVI: Syntheses, properties, and reactions of 8-aminoxanthines. Helv. Chim. Acta 2010, 93, 2115–2134. [Google Scholar] [CrossRef]
  19. Shawali, A.S.; Mosselhi, M.A.; Altablawy, F.M.A.; Farghaly, T.A.; Tawfik, N.M. Synthesis and tautomeric structure of 3,7-bis(arylazo)-6-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazoles in ground and excited states. Tetrahedron 2008, 64, 5524–5530. [Google Scholar] [CrossRef]
  20. Shawali, A.S.; Mosselhi, M.A.; Farghaly, T.A.; Shehata, M.R.; Tawfik, N.M. Synthesis and tautomeric structure of 3,6-bis(arylazo)pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-diones. J. Chem. Res. 2008, 452–456. [Google Scholar]
  21. Shawali, A.S.; Mosselhi, M.A.; Farghaly, T.A. Synthesis and tautomeric structure of 2-arylazo-4H-imidazo[2,1-b][1,3,4]-thiadiazines. J. Chem. Res. 2007, 479–483. [Google Scholar]
  22. Shawali, A.S.; Abdallah, M.A.; Mosselhi, M.A.N.; Mohamed, Y.F. Synthesis and tautomeric structure of 1,2-bis(7-arylhydrazono-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)ethanes. Z. Naturforsch. B: Chem. Sci. 2002, 552–556. [Google Scholar]
  23. Mosselhi, M.N.; Abdallah, M.A.; Mohamed, Y.F.; Shawali, A.S. Synthesis and tautomeric structure of 7-arylhydrazono-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines. Phosphorus Sulfur Silicon 2002, 177, 487–496. [Google Scholar] [CrossRef]
  24. Mosselhi, M.A.N.; Abdallah, M.A.; Riyadh, S.M.; Harhash, A.E.; Shawali, A.S. Tautomerism and reactions of 1H-1,2,4-thiazole-5-thiones with hydrazonoyl halides. J. Prakt. Chem. 1998, 340, 160–164. [Google Scholar]
  25. Hlavka, J.J.; Bitha, P.; Lin, Y.; Strohmeyer, T. Synthesis and reactions of 2,3-diamino-4(3H)-pyrimidinones and 3-amino-2-hydrazino-4(3H)-pyrimidinones. J. Heterocycl. Chem. 1984, 21, 1537–1541. [Google Scholar] [CrossRef]
  26. Essassi, E.M.; Lavergne, J.P.; Viallefont, P.; Daunis, J. Recherches en série triazepine-1,2,4: 1-détermination de la structure de la triazolotriazépinone obtenue par action de l'acétylacétate d'éthyle sur le diamino-3,4 triazole-1,2,4. J. Heterocycl. Chem. 1975, 12, 661–663. [Google Scholar]
  27. Hassan, K.M.; Ahmed, R.A.; Abdel-Hafez, S.H.; Abdel-Azim, M.A. Condensed thioxocyclopentapyridine (isoquinoline)-1,2,4-azines. Phosphorus Sulfur Silicon 2006, 181, 481–496. [Google Scholar]
  28. Romano, C.; De La Cuesta, E.; Avendano, C.; Florencio, F.; Sainz-Aparicio, J. Reactions of 1,2-diaminobenzimidazoles with β-dicarbonyl compounds. Tetrahedron 1988, 44, 7185–7192. [Google Scholar]
  29. Shawali, A.S.; Sherif, S.M.; Farghaly, T.A.; Shehata, M.R.; Darwish, M.A.A. Synthesis and tautomeric structure of the azo-coupling products of 2-methyl-7-phenylpyrimido[1,2-b][1,2,4]triazepine-4,9(3H,5H)-dione. J. Chem. Res. 2007, 44–47. [Google Scholar]
  30. Jones, R.; Ryan, A.J.; Sternhell, S.; Wright, S.E. The structures of some 5-pyrazolones and derived 4-arylazo-5-pyrazolones. Tetrahedron 1963, 19, 1497–1507. [Google Scholar]
  31. Smania, J.A.; Monache, F.D.; Smania, E.F.A.; Cuneo, R.S. Antibacterial activity of steroidal compounds isolated from Ganoderma applanatum (Pers.) Pat. (Aphyllophoromycetideae) fruit body. Int. J. Med. Mushrooms 1999, 1, 325–330. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of the compounds 4 and 6 are available from the authors.

Share and Cite

MDPI and ACS Style

Farghaly, T.A.R.; Edrees, M.M.; Abdelnabi Mosselhi, M. Synthesis, Tautomeric Structure and Antimicrobial Activity of 3-Arylhydrazono-4-phenyl-[1,2,4]-triazepino[2,3-a]quinazoline-2,7(1H)-diones. Molecules 2012, 17, 8483-8493. https://doi.org/10.3390/molecules17078483

AMA Style

Farghaly TAR, Edrees MM, Abdelnabi Mosselhi M. Synthesis, Tautomeric Structure and Antimicrobial Activity of 3-Arylhydrazono-4-phenyl-[1,2,4]-triazepino[2,3-a]quinazoline-2,7(1H)-diones. Molecules. 2012; 17(7):8483-8493. https://doi.org/10.3390/molecules17078483

Chicago/Turabian Style

Farghaly, Thoraya Abdel Reheem, Mastoura Mohamed Edrees, and Mosselhi Abdelnabi Mosselhi. 2012. "Synthesis, Tautomeric Structure and Antimicrobial Activity of 3-Arylhydrazono-4-phenyl-[1,2,4]-triazepino[2,3-a]quinazoline-2,7(1H)-diones" Molecules 17, no. 7: 8483-8493. https://doi.org/10.3390/molecules17078483

Article Metrics

Back to TopTop